Pro Medicus, Ltd. · ASX:PME

Pro Medicus — FY2021 Earnings Presentation

43 slides from Pro Medicus's earnings presentation, August 2021

  1. Slide 1: FY 2021 Results Presentation

    FY 2021 RESULTS PRESENTATION August 2021

  2. Slide 2: Pro Medicus (ASX:PME)

    PRO MEDICUS (ASX:PME) Healthcare IT company specializing in Enterprise Imaging and Radiology Information System (RIS) software. Leading edge products, growing global presence. EU HQ/R&D Berlin GmbH U.S. HQ San Diego CA GROUP HQ Melbourne AUS OVER 40+ SOFTWARE ENGINEERS 2

  3. Slide 3: Product Suite

    ASX:PME VISAGE RIS VISAGE 7 OEM PRODUCT SUITE 3

  4. Slide 4: Results FY 2021

    RESULTS FY 2021 $67.9M $30.85M $42.63M 63.2% Underlying Profit Underlying EBIT Revenue after tax Profit margins up 19.5% up 33.7% Before Tax up 41.0% $61.8M $0.15 Cash Company Strong Full year & debt balance dividend FF Investments free sheet Up 25% up 42.4%

  5. Slide 5: Sales Pipeline FY21 Full Year

    SALES PIPELINE FY21 Full Year Continues to grow STRONGLY University of California $25M/7 years $10M/7 years $18M/5 years $40M/7 years $31M/7 years $14M/8 years New Contract New Contract New Contract New Contract New Contract New Contract SEPTEMBER 2020 OCTOBER 2020 DECEMBER 2020 JANUARY 2021 FEBRUAR

  6. Slide 6: In Review

    IN REVIEW 2020-2021 Top Hospitals 6

  7. Slide 7: FY 2021 Revenue Split

    FY 2021 Revenue Split $80,000,000 Full year revenue split Exam/licence revenue*** Support/baseline revenue*** Capital revenue (net of hardware) Professional Services*** Archive data migration ***Recurring revenue $70,000,000 $3,413,000 $6,047,000 $60,000,000 $4,609,000 $50,000,000 $17,484,000 $6,464

  8. Slide 8: Operational (Transaction) Model

    OPERATONAL (TRANSACTION) MODEL • Used in vast majority of US contracts • Delivered as SaaS model • Now used in RIS contracts in AUS • Model based on transaction minimums • Forward revenue > A$320M/5 years* • Upside as client examination volumes grow • Annuity style revenue stream – greater predictab

  9. Slide 9: Exam (Transaction) Revenue

    EXAM (TRANSACTION) REVENUE • Recurring in nature • Increased by 16% YoY (28% on constant currency basis) • Growth to continue for FY 2022 (Northwestern, NYU, MedStar & others) • New sites coming online in 1st Half FY22 (Intermountain, 2 UC campuses & UVM) • Growth from existing clients (organic and

  10. Slide 10: Professional Services

    PROFESSIONAL SERVICES • Project planning, training & implementation • Revenue spread over the length of the contract - new accounting standards (AASB 15) • Recurring in nature ~ 10% contract value • Data Migration as part of Visage 7 Open Archive sale – once off 10

  11. Slide 11: Operating Leverage

    OPERATING LEVERAGE • Highly scalable offering • No capex (HW) – SW only model • Training & Installation – charged as professional services • Contained cost base • High operating leverage • Margin continues to grow as footprint increases 11

  12. Slide 12: COVID-19

    COVID-19 • PME/Visage transitioned to WFH in mid-March 2020 • Operating at 100% capacity • Sales and marketing efforts continued throughout • “Thinness” of the technology enabled large scale remote demonstrations • New opportunities despite COVID restrictions • Visage 7 - enables radiologists to sea

  13. Slide 13: Visage RIS

    VISAGE RIS @VISAGERIS TECHNOLOGIST OCT TRANSCRIPTIONIST SEARCH OFFICE CLAIMING SETUP Recent| ¥ Dr R Simps Appointments Northern 1 "Wisage Ganeral Hospial 4 tue,17-.0-2017 > TY MET TAMPA © Patent © Procedure (| Cancelled Blocked Visage X-ray ~ sa [Visage CT + Visage US Room 1 > ren | Visage US Room 2

  14. Slide 14: Visage RIS

    VISAGE RIS • Long term (5 year) contracts with Primary Healthcare and I–MED, the 2 biggest radiology providers in AUS • HIS (Healius) rollout now complete • Upside via organic and M&A growth (I-MED) • Increased market interest – new opportunities • PME undisputed market leader

  15. Slide 15: Visage 7

    VISAGE 7 Continues to be #1 in Speed, Functionality and Scalability SPEED FUNCTIONALITY SCALABILITY

  16. Slide 16: Massive Data Explosion

    MASSIVE DATA EXPLOSION • High density Multi-slice CT - 10,000+ images • HD Breast Tomosynthesis - 6 GB+ • Optoacoustic breast ultrasound - 10+ GB • Total Body PET Scan - 10+ GB • 7T MRI - much larger than 3T

  17. Slide 17: Legacy Technology

    LEGACY TECHNOLOGY “Compress and Send” MODALITIES PACS RADIOLOGIST/CLINICIAN

  18. Slide 18: Solution: Visage 7 Streaming Technology

    SOLUTION: VISAGE 7 STREAMING TECHNOLOGY

  19. Slide 19: NYU Langone

    NYU LANGONE • $25 Million over 7 years • Voted in the top 10 Hospitals in North America • Transaction based licensing model with upside • Teaching hospital for the Grossman School of Medicine • Implementation completed in June 2021 • Visage to setup new R&D hub in NYC starting August 2021 20

  20. Slide 20: LMU Klinikum - Munich

    LMU KLINKUM - MUNICH • $10M – 7-year deal • One of Europe’s largest teaching hospitals • 2nd major hospital contract in Germany • Visage 7 Viewer and Visage 7 Open Archive • Breaks the mold of “one-stop-shop” modality vendor systems • Paves the way for future European sales • Implementation complete

  21. Slide 21: Zwanger Pesiri

    ZWANGER PESIRI • $8.5M -5-year renewal contract • One of the largest private outpatient groups in the US • Increased minimum contract value by 70% • Visage technology key enabler of practice growth • Validates Visage’s unique value proposition 22

  22. Slide 22: MedStar Health

    MEDSTAR HEALTH • $18M-5-year deal • Replaces legacy PACS across 10 hospitals • Largest health system in the Maryland/DC region • Contract for all three Visage modules –Viewer, Open Archive and Workflow • Visage 7 platform to be fully deployed in the public cloud • Extends PME’s rapidly growing footp

  23. Slide 23: Intermountain Healthcare

    INTERMOUNTAIN HEALTHCARE • $40M – 7-year deal • Largest healthcare provider in the Intermountain West • Visage to replace legacy PACS across 24 hospitals and more than 200 clinics • Contract includes the Visage 7 Viewer and Open Archive • Visage 7 to be fully deployed in the public cloud • Extends P

  24. Slide 24: University of California Health System

    UNIVERSITY OF CALIFORNIA HEALTH SYSTEM • $31M – 7-year deal • 5 leading academic campuses - UCLA, UCSF, UCSD, UC Davis and UC Irvine • Unifying all 5 academic campuses on a single diagnostic imaging platform • Visage 7 to be deployed in the public cloud • Further extends PME’s footprint in tier 1 ac

  25. Slide 25: University of Vermont Medical Center

    UNIVERSITY OF VERMONT MEDICAL CENTER • $14M – 8-year deal • Visage to replace multiple legacy PACS systems • Visage 7 to be deployed in the public cloud • Extends PME’s US academic institution footprint • Transaction-based model with potential upside 26

  26. Slide 26: Fast Track Implementation

    FAST TRACK IMPLEMENTATION • All implementations on or ahead of schedule • Fast track methodology continues to deliver • Large scale projects completed in under 1/4 the time of industry norm • Delivers huge savings for client • Frees PME staff for other jobs • Reduces barrier to change • OSU first 10

  27. Slide 27: Key Implementations

    KEY IMPLEMENTATIONS FY21 OTHER SITES August 2020 May 2021 June 2021 June/July 2021 July to April 100% Remote Onsite 100% Remote Hybrid Remote & 100% Remote Onsite 28

  28. Slide 28: Visage – Proven ROI

    VISAGE – PROVEN ROI Significant IT & Unparalleled Increase in Greater Clinical Infrastructure Savings Radiologist Efficiency Accuracy Improved Physician Delivers Superior Engagement Value Proposition 29

  29. Slide 29: Visage – Clinical ROI

    VISAGE – CLINICAL ROI Improved Physician Engaement 30

  30. Slide 30: Growth Strategy

    GROWTH STRATEGY New product offerings Transaction growth Extend to new from existing clients geographical markets Leverage R&D capability Expand footprint – to introduce next new clients generation products 31

  31. Slide 31: North American Pipeline

    NORTH AMERICAN PIPELINE Prospects Progressing through Network Effect various stages of the cycle Opportunities Increased as a result of recent high- profile wins Last 12 months - Pipeline Robust significant increase in number of inbound RFPs In terms of quality and quantity of opportunities 32

  32. Slide 32: Visage 7 Open Archive

    VISAGE 7 OPEN ARCHIVE • Same highly scalable Visage 7 platform • Interoperable – works in complex environments • Enables choice of modular or single vendor solutions • Three recent sales - Viewer and Visage 7 Open Archive • Pipeline includes Visage 7 Open Archive opportunities • Key component of Vis

  33. Slide 33: Visage 7 Workflow

    VISAGE 7 WORKFLOW • Adds to Visage 7 Viewer and Open Archive modules • Based on over 30 years experience in Worklist SW • Allows PME to offer single vendor solution • Integral part of Visage in the Cloud SaaS solution • Ability to interface with broad range of AI algorithms • Transaction based model

  34. Slide 34: New Products

    NEW PRODUCTS • Single viewer for ALL images in the medical record (EMR) • Radiology/Cardiology (DICOM format) • Non-radiology– reflected light – hi-res photos & videos • Visage 7 technology ideally suited • Increases Visage value proposition • Growth opportunities within existing contracts

  35. Slide 35: Visage in the Cloud

    VISAGE IN THE CLOUD • Visage 7 – fully Cloud native • Same ultrafast performance as on-premise • Full Visage 7 functionality • Security and scale of the cloud • Complete PACS deployment or as backup/disaster recovery • Suitable for all size implementations • Opens new market opportunities • Signific

  36. Slide 36: Visage in the Cloud: Cloud Native

    VISAGE* 7 IN THE CLOUD CLOUD NATIVE ' 4 Cloud Object Storage MASSIVELY PARALLEL 1/0 Digital Alchemy for Imaging in the Cloud Faster-than-flash performance using secure, low-cost storage, We re-architected Vi intelligently leverage the best capabilities of object-based cloud storage. Up to 60 to clou

  37. Slide 37: Visage 7 AI platform

    VISAGE 7 • Unique end to end solution • Supports both research and production environments on a single platform • Based on market leading Visage 7 technology • Enables Visage clients to fast-track AI as part of their imaging strategy 39

  38. Slide 38: Visage 7 AI Accelerator Platform

    VISAGE 7 • Visage AI Accelerator Platform– streamlines AI algorithm development • Optimised for AI data curation and validation • Open API - seamless integration • AI Ecosystem - 3rd party and Visage developed algorithms • Joint development/commercialisation opportunities - 3rd party and academic cl

  39. Slide 39: AI Research Leadership

    AI RESEARCH LEADERSHIP Malte Westerhoff, PhD Chief Technology Officer Detlev Stalling, PhD Head of Development MingDe Lin, PhD Director, Clinical Research North America 41

  40. Slide 40: Research Collaboration Agreements (RCA)

    RESEARCH COLLABORATION AGREEMENTS (RCA) 42

  41. Slide 41: Breast Density - AI

    BREAST DENSITY - AI • First diagnostic AI algorithm produced by Visage • Developed in collaboration with breast imaging team at Yale • Provides “on-the-fly” AI assessment of breast density • Previewed at RSNA 2019 as WIP • FDA approval – February 2021 • A model for future AI development 43

  42. Slide 42: HIMSS21

    V\ HIMSS21 VISAGE TMAGING Platform: For The Future — Powered. By Speed. Lx . prosmedicus & SR SUPPORT. aU SUES Visace IMAGING’ 44

  43. Slide 43: Thank You

    A’\A Gy 4 VV . Wy THANK YOU pro+medicus

Pro Medicus — FY2021 Earnings Presentation on 6ix